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In 2008, half of the 15 best-selling cardio-
vascular drugs (those with sales of over $2 
billion), the sartans, were developed over 
30 years ago. A lipid-lowering drug devel-
oped over 40 years ago (fenofibrate) also 
made it into the top fifteen. Rare are those 
developed more recently. One example is 
ezetimibe developed in the 1990s. Drugs 
acting on cholesterol levels such as fenofi-
brate, ezetimibe and the statins represent 
over a quarter of the top fifteen. There are 
many reasons behind these figures – the 
duration of the drug development process 
from synthesis to marketing, the economics 
of the pharmaceutical industry that in some 
markets make it more financially reward-
ing to copy the others than to innovate, etc. 
Albeit, looking at these figures, a pessimist 
would be tempted to say that cardiovascu-
lar pharmacologists have shown a certain 
lack of imagination – an optimist would say 
that there is a large number of potential tar-
gets out there just waiting to be discovered 
and developed.
Frontiers in cardiovascular and smooth 
muscle pharmacology will focus on such 
potential targets and concepts, as well as 
on the new technology and methodology 
required to investigate them.
Classical  drug  research  and  develop-
ment was based on the identification of 
selective membrane targets such as recep-
tors or ion channels that promote a spe-
cific reaction to a given drug in the midst 
of the chemical cacophony of the receptor 
or ion channel biophase. The invention by 
Sir James Black of propranolol, the beta-
adrenoreceptor  antagonist,  in  the  1960s, 
was based on the pioneering work done by 
himself and others on the development of 
specific ligands for specific adrenoreceptor 
types. This drug revolutionized the manage-
ment of angina pectoris and is one of the 
most important contributions to clinical 
pharmacology of the 20th century. In the 
1960s Black was also cogitating on other 
applications  of  receptor  pharmacology. 
He thought that the   histamine antagonists 
available at that time were analogous to 
alpha-adrenoreceptor antagonists and that 
the equivalent of propranolol was needed 
to block histamine-stimulated acid secre-
tion in the stomach. This lead in the 1970s 
to the H2-receptor antagonist programme 
and cimetidine. Such an approach is still 
highly relevant today and investigation into 
the roles of 5-HT2Band 5-HT7 receptors 
as well as 5-HT3-receptor subunits in the 
gastrointestinal pharmacology and physiol-
ogy of 5-HT is of prime importance. Given 
that there are some 800 G-protein coupled 
receptors, this classical membrane receptor 
approach still has a bright future.
Another  concept  that  dates  from  the 
1960s is that of receptor desensitization. At 
that time the idea started to emerge that 
agonists may not only stimulate receptors 
but  that  they  can  also  desensitize  them. 
Interesting  work  is  now  being  done  on 
the desensitization of G-protein coupled 
receptors  through  phosphorylation  and 
the recruitment of arrestins. This process 
appears to be uniquely related to the cell 
type  in  which  the  receptor  is  expressed, 
thus  opening  up  an  avenue  for  research 
into agents that selectively modulate recep-
tor desensitization in one type of cell but 
not in another.
Another approach to the development 
of therapeutic agents is to interfere with 
the signal before it reaches the receptor or 
whatever its target may be. A novel way to 
do this is to use “immunodrugs” that are 
therapeutic vaccines intended for the treat-
ment and prevention of common chronic 
diseases. In hypertension current vaccina-
tion approaches target angiotensin I and 
II. It is interesting that the vaccine appears 
to be very effective in the early morning, a 
critical time of day when adverse cardiovas-
cular events occur frequently.
Pharmacology went beyond the recep-
tor many years ago. Over the years there 
has been growing interest in the cellular 
mechanisms  of  signal  transduction  and 
amplification  behind  receptors  and  the 
clinical applications of these mechanisms. 
For example, work on the erythropoietin 
intracellular signalling cascade, has shown 
that this agent can limit infarct size follow-
ing myocardial ischemia by activating sur-
vival kinases of the RISK pathway including 
PI3K/Akt and ERK1/2during reperfusion.
The development of new physiological 
concepts will also furnish new ideas for cardi-
ovascular and smooth muscle pharmacology. 
It was recently showed that in the elderly an 
increase in pulse blood pressure arising from 
increased large artery stiffness can have det-
rimental effects on cardiovascular structure 
and function. This has opened up an excit-
ing domain of research into agents capable 
of directly modifying wall stiffness (rather 
than arterial diameter as was classically the 
case).  Such  agents  interfere,  for  example, 
with physicochemical processes such as gly-
cation and calcification of long-lived sclero-
proteins (collagen and elastin). The research 
and development of these agents will require 
novel pharmacological paradigms.
Modulation of arterial diameter has not, 
however, delivered all of its secrets. Another 
interesting new concept is that of the reset-
ting of myogenic tone. The arteriolar myo-
genic response is defined as vasoconstriction 
to an increase in intra-luminal pressure and 
dilation to a reduction in pressure. This 
response  assures  the  control  of  micro-
vascular diameter and hence tissue blood 
flow. Although progress has been made in 
research on the sensory apparatus and cel-
lular mechanisms involved, other new areas 
like the pharmacological modulation of the 
interactions between matrix proteins and 
the cell membrane are opening up.
Developments  in  drug  formulation 
and delivery systems will also be impor-
tant in future therapy. Thus, for example, 
non-invasive  delivery  systems  represent 
a novel approach for gene, cell and drug 
delivery to damaged tissue. An example of Atkinson  Cardiovascular and smooth muscle pharmacology
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smooth  muscle  pharmacology  hopes  to 
bring  you  the  up-to-date  developments 
in this science.
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involve the application of systems biology 
to pharmacology and drug development. 
Systems  biology  describes  complex  bio-
logical systems with the aim of developing 
predictive  models  of  disease.  Genomics, 
proteinomics  and  metabolomics  have 
accelerated understanding in disease mod-
els and mathematical simulations integrat-
ing knowledge of organ and system-level 
responses can help identify drug targets in 
disease.
Modern day cardiovascular and smooth 
muscle pharmacology represents a fasci-
nating,  multi-faceted,  fast    developing 
science.  Frontiers  in  cardiovascular  and 
this is ultrasound-mediated micro-bubble 
destruction that has been applied in the 
targeted  delivery  of  genes,  drugs  and 
stem cells to the myocardium following 
infarction.
Advances in modelling are also proving 
useful to pharmacological drug develop-
ment. Pharmacokinetics promises to bring 
new  facets  to  drug  research.  The  use  of 
pharmacokinetic-pharmacodynamic mod-
elling will lead to better understanding of 
drug efficacy and safety by predicting effi-
cacy and safety in humans on the basis of 
bioassay data and data from in vivo safety 
  pharmacology. Other modelling approaches 